<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1628">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02061800</url>
  </required_header>
  <id_info>
    <org_study_id>AAAK8060</org_study_id>
    <nct_id>NCT02061800</nct_id>
  </id_info>
  <brief_title>CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant</brief_title>
  <official_title>CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diane George, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a research study involving subjects who are diagnosed with a malignant
      disease, that has either failed standard therapy or is unlikely to be cured with standard
      non-transplant therapy, who will receive a peripheral blood stem cell transplant. A
      malignant disease includes the following: Chronic Myeloid Leukemia (CML) in chronic phase,
      accelerated phase or blast crisis; Acute Myelogenous Leukemia (AML); Myelodysplastic
      Syndrome (MDS); Juvenile Myelomonocytic Leukemia (JMML); Acute Lymphoblastic Leukemia (ALL);
      or Lymphoma (Hodgkin's and Non-Hodgkin's)  The purpose of this study is to learn more about
      the effects of CD34+ stem cell selection on graft versus host disease (GVHD) in children,
      adolescents and young adults. CD34+ stem cells are the cells that make all the types of
      blood cells in the body. GVHD is a condition that results from a reaction of transplanted
      donor T-lymphocytes (a kind of white blood cell) against the recipient's body and organs.
      Study subjects will be offered treatment involving the use of a Miltenyi CliniMacs CD34+
      selection device to remove T-cells from a peripheral blood stem cell transplant in order to
      decrease the risk of acute and chronic GVHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD34+ stem cells (the cells that make all the types of blood cells in the body) are selected
      (removed) from the donor's peripheral blood stem cells. In doing this, T-cells (a type of
      blood cell) are also removed. T-cells are the cells which are responsible for severe acute
      and chronic graft versus host disease (GVHD). GVHD is a condition that results from a
      reaction of the transplanted donor T-lymphocytes (a kind of white blood cell) against the
      body and organs. There are two forms: acute (early) and chronic (late). Acute GVHD may
      produce skin rashes, liver disease, diarrhea, and an increased risk of infection. Chronic
      GVHD can also appear in subjects without prior acute GVHD. Chronic GVHD may also produce
      skin rashes, liver disease, diarrhea and an increased risk of infection. Chronic GVHD may be
      mild and respond to agents which suppress the immune system, or it could be very severe. It
      may also last for over a year.

      Once this CD34 selection process is complete, the CD34+ stem cell AlloSCT is given to the
      recipient without most of the T-cells to see if this therapy will lessen the incidence and
      seriousness of graft versus host disease (GVHD). CD34+ stem cell selection AlloSCT has been
      studied in adults with malignant and non-malignant disease with successful engraftment and
      has shown some improvement in GVHD. We do not know if CD34+ stem cell selection will work to
      prevent severe GVHD in children, adolescents and young adults.

      Subjects are being offered this experimental treatment involving the use of a Miltenyi
      CliniMacs CD34+ selection device to remove T-cells from the peripheral blood stem cell
      transplant in order to decrease the risk of acute and chronic GVHD. There will be about 25
      subjects participating in this study at Columbia University Medical Center. The purpose of
      this study is to learn more about the effects of CD34+ stem cell selection on GVHD in
      children, adolescents and young adults.

      The goals of this study are:

        -  To determine how often acute GVHD occurs and how severe the acute GVHD is in the
           children, adolescents and young adults receiving CD34+ selection of their peripheral
           blood stem cell transplant from a family member or adult unrelated donor.

        -  To determine how often primary graft failure and secondary graft failure occurs in the
           children, adolescents and young adults receiving a peripheral blood stem cell
           transplant from a family member or adult unrelated donor.

        -  To see how quickly neutrophils (infection fighting white blood cells) will recover
           following CD34+ selection of their peripheral blood stem cell transplant from a family
           member or adult unrelated donor.

        -  To see if the time for the immune system (the body's defense system) to recover will
           benefit from receiving CD34+ selection of their peripheral blood stem cell transplant
           from a family member or adult unrelated donor.

        -  To see how often bacterial, viral, fungal and atypical mycobacteria (TB-like)
           infections will occur in the children, adolescents and young adults receiving CD34+
           selection of their peripheral blood stem cell transplant from a family member or adult
           unrelated donor.

      No tests will be performed for research purposes only. All required testing in this protocol
      is for the purpose of standard of care clinical assessment specific to the subject's
      disease. The only procedure specific to research will be the selection of CD34+ cells from
      the donor's peripheral blood stem cells using the Miltenyi Clinimacs CD34+ selection device.

      Study specific requirements occur up to 2 years post-transplant, although the study team
      will collect data on the progress of subjects yearly until termination of the study to
      observe if subjects are responding to therapy and have no worsening GVHD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of acute GVHD</measure>
    <time_frame>Up to 2 years post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Acute GVHD will be assessed and graded with standard NCI grading criteria.Evaluated daily while hospitalized, then weekly (1-60 days post-transplant), as clinically indicated (60-365 days post transplant), then 1 year, 1.5 years, 2 years and yearly (366+ days post-transplant)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of chronic GVHD</measure>
    <time_frame>Up to 2 years post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Chronic GVHD will be assessed and graded with standard NCI grading criteria. Evaluated daily while hospitalized, then weekly (1-60 days post-transplant), as clinically indicated (60-365 days post transplant), then 1 year, 1.5 years, 2 years and yearly (366+ days post-transplant)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of acute GVHD</measure>
    <time_frame>Up to 2 years post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Actue GVHD will be assessed and graded with standard NCI grading criteria. Evaluated daily while hospitalized, then weekly (1-60 days post-transplant), as clinically indicated (60-365 days post transplant), then 1 year, 1.5 years, 2 years and yearly (366+ days post-transplant)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of chronic GVHD</measure>
    <time_frame>Up to 2 years post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Chronic GVHD will be assessed and graded with standard NCI grading criteria. Evaluated daily while hospitalized, then weekly (1-60 days post-transplant), as clinically indicated (60-365 days post transplant), then 1 year, 1.5 years, 2 years and yearly (366+ days post-transplant).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of primary graft failure</measure>
    <time_frame>42 (or more) days post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary graft rejection is defined as the presence of &lt; 20% donor cells assessed by bone marrow or peripheral blood chimerism assays on day 42 post-transplant. Infusion of a second stem cell product on or prior to day 42 post-transplant will be considered primary graft rejection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of secondary graft failure</measure>
    <time_frame>42 (or more) days post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>The presence of &lt; 20% donor derived hematopoietic cells in peripheral blood or bone marrow after day 42 post-transplant in a patient with prior evidence of &gt; 20% donor cells will be considered late graft rejection. Also, infusion of a second stem cell product beyond day 42 post initial transplant will be considered late graft rejection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Up to 1 year post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be assessed multiple times while hospitalized, 1-60 days post transplant, 100 days post-transplant, 180 days post-transplant, and 1 year post transplant.  Neutrophil engraftment is defined as the first of three days following the neutrophil nadir with an absolute neutrophil count above 500/mm3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to immune reconstitution</measure>
    <time_frame>Up to 2 years post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immune reconstitution studies will be conducted (For T-cell, B-cell, natural killer (NK)-cell and immunoglobulins) 60 days post-transplant, 100 days post-transplant, 150 days post-transplant, 180 days post-transplant, 270 days post-transplant, 1 year post-transplant, and 2 years post transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection complications including bacterial, viral, fungal and atypical mycobacterial and other infections</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be assessed weekly or more as indicated until 84 or 100 days post-transplant, then as clinically indicated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>Up to 1 year post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be assessed multiple times while hospitalized, 1-60 days post transplant, 100 days post-transplant, 180 days post-transplant, and 1 year post transplant</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Chronic Myeloid Leukemia (CML)</condition>
  <condition>Acute Myelogenous Leukemia (AML);</condition>
  <condition>Myelodysplastic Syndrome (MDS);</condition>
  <condition>Juvenile Myelomonocytic Leukemia (JMML);</condition>
  <condition>Acute Lymphoblastic Leukemia (ALL);</condition>
  <condition>Lymphoma (Hodgkin's and Non-Hodgkin's)</condition>
  <arm_group>
    <arm_group_label>Full intensity with Total body irradiation (TBI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will start their pre-conditioning regimen on 8 days before scheduled transplant. Fractionated total body irradiation (TBI) will be administered twice daily for 3 days on the 6th, 7th, and 8th before transplant. Patients will receive Thiotepa on the 4th and 5th day before transplant, Cyclophosphamide on the 2nd and 3rd day before transplant, and Alemtuzumab on the 1st-5th day(s) before transplant. Then the stem cell infusion will be performed. GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Full intensity without TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will start their pre-conditioning regimen 9 days before their scheduled transplant. Patients will receive busulfan twice daily on the 5th-8th day before transplant and Melphalan on the 2nd-4th days before transplant and Alemtuzumab on the 1st-5th day before transplant. Subjects will then undergo with their stem cell infusion and GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after their transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced Toxicity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will begin tacrolimus on the first day of conditioning (8 days before scheduled transplant). Patients will receive alemtuzumab on the 3rd-7th day before transplant; busulfan twice daily on the 5th-8th day before transplant; and fludarabine on the 2nd-7th day before transplant. The stem cell infusion will be performed and GVHD prophylaxis will consist of tacrolimus only.
For patients with a prior history of hepatic toxicity and/or high-risk for veno-occlusive disease (VOD) or other liver toxicity post stem cell transplant, melphalan at 70 mg/m2 will be substituted for Busulfan on the 8th and 9th day before transplant, followed by fludarabine on the 2nd-7th day before transplant and alemtuzumab on the 3rd-7th day before transplant. The stem cell infusion will be performed and GVHD prophylaxis will consist of tacrolimus only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACS CD34+ Reagent System</intervention_name>
    <description>The CliniMACSÂ® Reagent System (Miltenyi Biotec, Bergisch Gladbach, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.</description>
    <arm_group_label>Full intensity with Total body irradiation (TBI)</arm_group_label>
    <arm_group_label>Full intensity without TBI</arm_group_label>
    <arm_group_label>Reduced Toxicity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <arm_group_label>Full intensity with Total body irradiation (TBI)</arm_group_label>
    <other_name>Thioplex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Full intensity with Total body irradiation (TBI)</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <arm_group_label>Full intensity with Total body irradiation (TBI)</arm_group_label>
    <arm_group_label>Full intensity without TBI</arm_group_label>
    <arm_group_label>Reduced Toxicity</arm_group_label>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <arm_group_label>Full intensity with Total body irradiation (TBI)</arm_group_label>
    <arm_group_label>Full intensity without TBI</arm_group_label>
    <arm_group_label>Reduced Toxicity</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>Full intensity without TBI</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <arm_group_label>Full intensity without TBI</arm_group_label>
    <arm_group_label>Reduced Toxicity</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>Reduced Toxicity</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: General Eligibility (All Patients)

          -  Must be &lt; 22 years of age

          -  Diagnosed with a malignant disease

          -  Must be fully informed about their illness and the investigational nature of the
             study protocol (including foreseeable risks and possible side effects), and must sign
             an informed consent

          -  For unrelated donor: A human leukocyte antigen (HLA) 8/10, 9/10 or 10/10 matched
             unrelated adult donor (MUD) will be required for study entry

          -  For related donor: A 5/10, 6/10, 7/10, 8/10, 9/10 or 10/10 matched (or partially
             matched) family donor will be required for study entry

          -  Adequate renal function

          -  Adequate liver function

          -  Adequate cardiac function

          -  Adequate pulmonary function

        Exclusion Criteria:

          -  Patients with documented uncontrolled infection at the time of study entry are not
             eligible

          -  Females who are pregnant or breast feeding at the time of study entry are not
             eligible
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Sosna, RN</last_name>
    <phone>212-305-2050</phone>
    <email>js4403@columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Sosna, RN</last_name>
      <phone>212-305-2050</phone>
    </contact>
    <investigator>
      <last_name>Diane George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>February 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Diane George, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics, Department of Pediatrics Onc/BMT/Hem</investigator_title>
  </responsible_party>
  <keyword>Unrelated donor transplant</keyword>
  <keyword>Allogenic Stem Cell Transplant</keyword>
  <keyword>Adult Bone Marrow Transplant</keyword>
  <keyword>Pediatric Bone Marrow Transplant</keyword>
  <keyword>Related donor transplant</keyword>
  <keyword>Haploidentical donor transplant</keyword>
  <keyword>Peripheral blood stem cell transplantation</keyword>
  <keyword>Non-malignant disease</keyword>
  <keyword>Malignant disease</keyword>
  <keyword>Bone marrow failure syndrome</keyword>
  <keyword>Severe Aplastic Anemia</keyword>
  <keyword>Severe Congenital Neutropenia</keyword>
  <keyword>Amegakaryocytic Thrombocytopenia</keyword>
  <keyword>Diamond-Blackfan Anemia</keyword>
  <keyword>Schwachman Diamond Syndrome</keyword>
  <keyword>Primary Immunodeficiency Syndrome</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Histiocytic Syndrome</keyword>
  <keyword>Familial Hemophagocytic Lymphocytosis</keyword>
  <keyword>Lymphohistiocytosis</keyword>
  <keyword>Macrophage Activation Syndrome</keyword>
  <keyword>Langerhans Cell Histiocytosis (LCH)</keyword>
  <keyword>Hemoglobinopathies</keyword>
  <keyword>Reduced-Intensity Conditioning</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Sickle Cell-beta-thalassemia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine monophosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Campath 1G</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
